Induction of antitumor immunity by intracerebrally implanted rat c6 glioma cells genetically engineered to secrete cytokines

Journal of Immunotherapy

Volumn 20, Issue 5, 1997, Pages 334-342

  Tseng, Sheng Hong ^a   Hwang, Lih Hwa ^a   Lin, Swei Ming ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Glioma; GM CSF; IL 2; IL 4; Tumorigenicity

Indexed keywords

CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 4; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER TRANSPLANTATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EOSINOPHIL; GENE THERAPY; GENETIC ENGINEERING; GENETIC TRANSDUCTION; GLIOMA CELL; HELPER CELL; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR IMMUNITY;

EID: 0031434207     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199709000-00002     Document Type: Article

References (37)

1. Medawar PB. Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 1948;29:58-69.
2. Tjuvajev J, Gansbacher B, Desai R, et al. RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-7. Cancer Res 1995;55:1902-10.
3. Scheinberg LC, Edelraan FL, Levy WA. Is the brain “an immu-nologically privileged site”? I. Studies based on intracerebral tumor homotransplantation and isotransplantation to sensitized hosts. Arch Neurol 1964;11:248-64.
4. Scheinberg LC, Kotsilimbas DG, Kargf R, Mayer M. Is the brain “an immunologically privileged site”? III. Studies based on homologous skin grafts to the brain and subcutaneous tissues. Arch Neurol 1966;15:62-7.
5. Young HF, Merchant RE, Apuzzo MLJ. Immunocompetence of patients with malignant glioma. In: Salcman M, ed. Concepts in neurosurgery. The cell biology of brain tumors. Baltimore: Wil-liams and Wilkins, 1991:211-27.
6. Ridley A, Cavernaugh JB. Lymphocytic infiltration in gliomas: evidence of possible host resistance. Brain 1971;94:117-24.
7. Stavrou D, Anzil AP, Weidenbach W, Rodt H. Immunofluorescence study of lymphocyte infiltration in gliomas: identification of T-lymphocytes. J Neurosci 1977;33:275-82.
8. Morantz RA, Wood GW, Foster M, Clark M, Gallahon M. Macrophages in experimental and human brain tumors. Part 2. studies of the macrophage content of human brain tumors. J Neurosurg 1979;50:305-11.
9. Saris SC, Spiess P, Lieberman DM, Lin S, Walbridge S, Oldfield EH. Treatment of murine primary brain tumors with systemic in-terleukin-2 and tumor-infiltrating lymphocytes. J Neurosurg 1992; 76:513-9.
10. Brooks WH, Netsky MG, Normansell DE, Horwitz DA. Depressed cell-mediated immunity in patients with primary intracranial tumors: characterization of a humoral immunosuppressive factor. J Exp Med 1972;136:1631-47.
11. Mahaley MS, Brooks WH, Roszman TL, Bigner DD, Duka L, Richardson S. Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients. J Neurosurg 1977;46:467-76.
12. Elliott LH, Brooks WH, Roszman TL. Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors. J Int Invest 1990;86:80-6.
13. Couldwell WT, Dore-Duffy P, Apuzzo MLJ, Antel JP. Malignant glioma modulation of immune function: relative contribution of different soluble factors. J Neuroimmunol 1991;33:89-96.
14. Lillehei KO, Mitchell DH, Johnson SD, McCleary EL, Kruse CA. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery 1991;28:16-23.
15. Roszman T, Elliott L, Brooks W. Modulation of T-cell function by gliomas. Immunol Today 1991;12:370.
16. Maxwell M, Galanopoulos T, Neville-Golden J, Antoniades NH. Effect of the expression of transforming growth factor-beta2 in primary human glioblastomas on immunosuppression and loss of immune surveillance. J Neurosurg 1992;76:799-804.
17. Lichtor T, Glick RP, Kim TS, Hand R, Cohen EP. Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells. J Neurosurg 1995;83:1038-1114.
18. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH. Intra-tumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 1989;70:175-82.
19. Merchant RE, McVicar DW, Merchant LH, Young HF. Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha: results of a phase clinical trial. J Neu-rooncol 1992;12:75-83.
20. Ram Z, Walbridge S, Heiss JD, Culver KW, Blease RM, Oldfield EH. In vivo transfer of the human interleukin-2 gene: negative results in experimental brain tumors. J Neurosurg 1994;80:535-40.
21. Yu JS, Wei MX, Chiocca EA, Martuza RL, Tepper RI. Treatment of glioma by engineered interleukin 4-secreting cells. Cancer Res 1993;53:3125-8.
22. Wakimoto H, Abe J, Tsunoda R, Aoyagi M, Hirawaka K, Hamada H. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res 1996;56:1823-33.
23. Hsieh CL, Chen BF, Wang CC, Liu HH, Chen DS, Hwang LH. Improved gene expression by a modified bicistronic retroviral vector. Biochem Biophys Res Commun 1995;214:910-7.
24. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
25. Chen BF, Hwang LH, Chen DS. Characterization of a bicistronic retroviral vector composed of the swine vesicular disease virus internal ribosomal entry site. J Virol 1993;67:2142-8.
26. Markowitz D, Goff S, Bank A. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol 1988;62:1120.
27. Markowitz D, Goff S, Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 1988; 167: 400-6.
28. Benda P, Lichtbody J, Sato G, Levine L, Sweet WH. Differentiated rat glial cell strain in tissue structure. Science 1968;161:370-1.
29. Benda P, Someda K, Messer J, Sweet WH. Morphological and immunochemical studies of rat glial tumors and clonal strains propagated in culture. J Neurosurg 1971;34:310-23.
30. Abbas AK, Lichtman AH, Pober JS, eds. Cellular and molecular immunology. Philadelphia: WB Saunders, 1991:225-43.
31. Glick RP, Lichtor T, Kim TS, Ilangovan S, Cohen EP. Fibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce anti tumor immunity to murine gliomas in vivo. Neu-rosurgery 1995;36:548-55.
32. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995; 13:399-415.
33. Bannerji R, Arroyo CD, Cordon-Cardo C, Gilboa E. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J Immunol 1994;152:2324-32.
34. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989;57:503-12.
35. Colombo MP, Modesti A, Parmiani G, Forni G. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res 1992; 52: 4853-7.
36. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-6.
37. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and longlasting antitumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.